Royalty Pharma Long-term financing receivables (net of allowances of $27 in 2026 and $34 in 2025) increased by 2.1% to $16.54B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.0%, from $15.03B to $16.54B. Over 5 years (FY 2020 to FY 2025), Long-term financing receivables (net of allowances of $27 in 2026 and $34 in 2025) shows an upward trend with a 5.6% CAGR.
Growth indicates a longer-term commitment to financing activities and potential for long-term interest income.
This represents the long-term portion of financing receivables that are not due within the next twelve months. It reflec...
Common for companies with significant captive finance operations, such as automotive or industrial manufacturers.
non_current_assets_notes_and_loans_receivable_net_noncurrent| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $12.93B | $14.01B | $13.72B | $13.47B | $13.42B | $14.29B | $13.49B | $13.66B | $13.27B | $13.23B | $14.09B | $13.47B | $13.89B | $14.97B | $15.13B | $15.03B | $15.13B | $15.76B | $16.21B | $16.54B |
| QoQ Change | — | +8.4% | -2.1% | -1.8% | -0.3% | +6.4% | -5.6% | +1.3% | -2.9% | -0.3% | +6.5% | -4.4% | +3.2% | +7.8% | +1.1% | -0.6% | +0.7% | +4.2% | +2.8% | +2.1% |
| YoY Change | — | — | — | — | +3.8% | +2.0% | -1.6% | +1.4% | -1.2% | -7.4% | +4.4% | -1.4% | +4.7% | +13.1% | +7.4% | +11.6% | +9.0% | +5.3% | +7.1% | +10.0% |